Rhythm Pharmaceuticals, Inc.'s SEC filings document a commercial-stage biopharmaceutical company whose disclosures center on IMCIVREE (setmelanotide), MC4R pathway rare-disease indications and related clinical and regulatory milestones. Recent Form 8-K reports include operating results, product-revenue commentary, FDA and European regulatory updates for acquired hypothalamic obesity, and trial disclosures for programs such as TRANSCEND and EMANATE.
Rhythm's proxy materials and governance filings disclose board composition, director elections, executive compensation, equity awards and shareholder voting matters. Other current reports record director changes, Regulation FD materials, presentations and press releases, tying corporate governance and public-company reporting to the company's rare neuroendocrine disease portfolio.
Rhythm Pharmaceuticals, Inc. (RYTM) director Christophe Jean reported a proposed sale of 10,000 common shares, with an aggregate market value of $1,074,800 and an approximate sale date of November 17, 2026. The shares were acquired from the issuer through exercise of stock options on November 17, 2026, with cash payment. Morgan Stanley Smith Barney LLC is listed as broker.
Rhythm Pharmaceuticals, Inc. (RYTM) reported third-quarter 2026 revenue of $92.128 million, versus $51.298 million a year earlier, and net loss of $41.369 million, down from $52.904 million.
For the first nine months, revenue was $223.494 million versus $132.504 million, while operating cash used was $56.399 million versus $90.286 million. Cash, cash equivalents and short-term investments totaled $320.9 million as of September 30, 2026; management believes existing cash resources can fund operations through at least the next 24 months.
On November 2, 2026, Rhythm amended its LGC license, agreeing to $350.0 million of additional consideration: $70.0 million within 15 business days of effectiveness, $100.0 million in September 2027 and 2028, and $80.0 million in September 2029. With LGC's prior written consent, the 2027, 2028 and 2029 payments may instead be satisfied through low single-digit royalty increases; potential commercial and developmental milestone payments are up to $405 million, inclusive of the original $205 million. Rhythm also entered a loan agreement providing for term-loan financing of up to $750.0 million: $250.0 million of initial loans to be funded at closing, $250.0 million of delayed draw A commitments subject to borrowing conditions, and up to $250.0 million of uncommitted delayed draw B loans subject to lenders' discretion.
Rhythm Pharmaceuticals (RYTM) reported third-quarter 2026 global IMCIVREE net product revenue of $92.1 million, up 29% sequentially and compared with $51.3 million in Q3 2025. Reimbursed patients worldwide increased 20% from Q2. Net loss attributable to common stockholders was $42.4 million, or $0.61 per share, versus $54.3 million, or $0.82 per share, a year earlier.
More than 700 patient start forms had been received from more than 500 prescribers for acquired hypothalamic obesity as of September 30, 2026, and the Japan commercial launch began October 13, 2026. Rhythm agreed to pay LG Chem $350 million in fixed payments over four years to reduce the royalty on net product revenue from its MC4R portfolio to 1%, beginning January 1, 2029, or at bivamelagon’s first commercial sale if earlier. A five-year term loan provides access to up to $750 million, including a $250 million initial draw. September 30, 2026 cash, cash equivalents and short-term investments of $320.9 million exclude the initial draw and a $70 million payment due to LG Chem.
Rhythm anticipates 2026 Non-GAAP Operating Expenses of $360 million to $380 million. Based on current operating plans, it expects its September 30 cash position to fund planned operations for at least 24 months and expects to initiate a pivotal Phase 3 bivamelagon trial in acquired hypothalamic obesity by year-end 2026.
JPMorgan Chase & Co. reported beneficial ownership of 3,563,667 shares of Rhythm Pharmaceuticals, Inc. common stock, equal to 5.1% of the class as of September 30, 2026. JPMorgan also identifies J.P. Morgan Trust Company of Delaware; J.P. Morgan Securities LLC; JPMorgan Chase Bank, National Association; JPMorgan Asset Management (UK) Limited; J.P. Morgan Investment Management Inc.; and J.P. Morgan Wealth Management Solutions Inc. as subsidiaries that acquired the reported security.
For Rhythm Pharmaceuticals, Inc. (RYTM), President and CEO David P. Meeker reported exercising options for 50,000 shares of common stock at an exercise price of $6.05 per share on September 14, 2026, and selling 50,000 shares in multiple transactions on the same day. The option exercise relates to awards granted in February 2017, and the exercise and sales were carried out under a Rule 10b5-1 trading plan adopted on June 15, 2026.
RHYTHM PHARMACEUTICALS, INC. (RYTM) is the issuer for which David Meeker has filed a notice of proposed sale of restricted or control securities under Rule 144. The notice covers a proposed sale of 50,000 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $5,235,500 as of the filing. The filing lists 68,852,082 shares of common stock outstanding and indicates the shares are to be sold on NASDAQ on or after September 14, 2026, following acquisition via exercise of stock options for cash.
RHYTHM PHARMACEUTICALS, INC. (RYTM) Chief Financial Officer Hunter C. Smith exercised 57,187 employee stock options on August 31, 2026 at an exercise price of $25.79 per share, receiving the same number of common shares. On the same date, he sold 62,774 common shares in multiple transactions at weighted average prices around $104.59, $105.37, and $106.20 per share, with each tranche executed in price ranges disclosed in the footnotes. The option exercised was granted on February 14, 2018 and vesting occurred in sixteen equal quarterly installments; 3,813 option shares remain outstanding, expiring February 13, 2028. All exercises and sales were made pursuant to a Rule 10b5-1 trading plan adopted on May 13, 2026.
RHYTHM PHARMACEUTICALS, INC. officer Hunter Smith filed notice of a proposed sale of 62,774 common shares, with an approximate sale date of August 31, 2026. The listed aggregate market value is $6,727,489.58.
The notice reports 68,852,082 shares outstanding.
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported that Chief Medical Officer Manher Joshi received equity awards. He was granted 50,000 stock options with an exercise price of $115.44 per share, expiring August 16, 2036. These options vest 25% after one year, then 6.25% every three months of continued service.
He also received 25,000 Restricted Stock Units, vesting 25% on September 1 of each of 2027, 2028, 2029, and 2030, becoming fully vested on September 1, 2030, subject to continued service. Following these grants, he holds 50,000 options and 25,000 RSUs directly.
Rhythm Pharmaceuticals, Inc. (RYTM) reports an initial statement of beneficial ownership on Form 3 for Joshi Manher, who serves as Chief Medical Officer. The filing lists no equity transactions or holdings and notes an attached Exhibit 24 for a Power of Attorney, authorizing filings to be made on the officer’s behalf.